{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:49:37Z","timestamp":1790272177176,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"325","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Morphologie"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.morpho.2015.01.003","type":"journal-article","created":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T04:37:47Z","timestamp":1429331867000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The use of animal models in multiple myeloma"],"prefix":"10.1016","volume":"99","author":[{"given":"H.","family":"Libouban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.morpho.2015.01.003_bib0415","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.morpho.2015.01.003_bib0420","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.morpho.2015.01.003_bib0425","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0430","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0435","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0440","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1365-2141.1999.01243.x","article-title":"Potential role of insulin-like growth factor binding protein-4 in the uncoupling of bone turnover in multiple myeloma","volume":"104","author":"Feliers","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0445","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0450","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.morpho.2015.01.003_bib0455","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0460","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0465","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0470","first-page":"227","article-title":"Mouse plasmacytoma: an experimental model of human multiple myeloma","volume":"86","author":"Gado","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.morpho.2015.01.003_bib0475","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0889-8588(05)70434-2","article-title":"Experimental plasmacytomagenesis in mice","volume":"11","author":"Potter","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.morpho.2015.01.003_bib0480","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2011-06-363887","article-title":"Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia","volume":"119","author":"LeGrand","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0485","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/1471-2164-8-302","article-title":"Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia","volume":"8","author":"Park","year":"2007","journal-title":"BMC Genomics"},{"key":"10.1016\/j.morpho.2015.01.003_bib0490","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/carcin\/13.10.1681","article-title":"Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations","volume":"13","author":"Potter","year":"1992","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.morpho.2015.01.003_bib0495","first-page":"8656","article-title":"BCL2 accelerates inflammation-induced BALB\/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations","volume":"63","author":"Silva","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.morpho.2015.01.003_bib0500","first-page":"546","article-title":"The role of interleukin-6 and interleukin-6\/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma","volume":"11","author":"Barille","year":"2000","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.morpho.2015.01.003_bib0505","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1084\/jem.182.1.243","article-title":"Interleukin 6 is essential for in vivo development of B lineage neoplasms","volume":"182","author":"Hilbert","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.morpho.2015.01.003_bib0510","first-page":"689","article-title":"Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB\/c mice","volume":"151","author":"Lattanzio","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0515","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ajh.23164","article-title":"Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma","volume":"87","author":"Henk","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0520","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0609.2005.00427.x","article-title":"The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB\/c mice by intraperitoneal injection of pristane","volume":"74","author":"Avcu","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0525","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V87.4.1495.bloodjournal8741495","article-title":"Development of an in vivo model of human multiple myeloma bone disease","volume":"87","author":"Alsina","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0530","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1359\/jbmr.1999.14.2.256","article-title":"Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice","volume":"14","author":"Hjorth-Hansen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.morpho.2015.01.003_bib0535","first-page":"6689","article-title":"Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID\/NOD in vivo model: biologic and clinical implications","volume":"63","author":"Mitsiades","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.morpho.2015.01.003_bib0540","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V95.3.1056.003k26_1056_1065","article-title":"Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice","volume":"95","author":"Pilarski","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0545","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood.V90.6.2437","article-title":"New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor","volume":"90","author":"Tsunenari","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0550","first-page":"711","article-title":"Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism","volume":"9","author":"Goto","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.morpho.2015.01.003_bib0555","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.morpho.2015.01.003_bib0560","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0301-472X(01)00618-X","article-title":"Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma","volume":"29","author":"Cruz","year":"2001","journal-title":"Exp Hematol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0565","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.11134","article-title":"RANK-Fc: a therapeutic antagonist for RANK-L in myeloma","volume":"97","author":"Sordillo","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.morpho.2015.01.003_bib0570","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.thj.6200052","article-title":"The 5TMM series: a useful in vivo mouse model of human multiple myeloma","volume":"1","author":"Asosingh","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.morpho.2015.01.003_bib0575","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2141.1995.tb03307.x","article-title":"The SCID mouse as a model for multiple myeloma","volume":"89","author":"Ahsmann","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0580","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood.V80.11.2843.2843","article-title":"Long-term engraftment of fresh human myeloma cells in SCID mice","volume":"80","author":"Feo-Zuppardi","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0585","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations","volume":"92","author":"Yaccoby","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0590","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0595","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.morpho.2015.01.003_bib0600","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2002-03-0939","article-title":"Antimyeloma efficacy of thalidomide in the SCID-hu model","volume":"100","author":"Yaccoby","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0605","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.morpho.2015.01.003_bib0610","first-page":"395","article-title":"Idiopathic paraproteinaemia. I. Studies in an animal model\u00a0\u2013\u00a0the ageing C57BL\/KaLwRij mouse","volume":"33","author":"Radl","year":"1978","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0615","first-page":"109","article-title":"Multiple myeloma and related disorders. Lessons from an animal model","volume":"47","author":"Radl","year":"1999","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.morpho.2015.01.003_bib0620","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.leukres.2006.05.014","article-title":"Absence of renal lesions in C57BL\/KaLwRij mice with advanced myeloma due to 5T2MM cells","volume":"30","author":"Libouban","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.morpho.2015.01.003_bib0625","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.morpho.2015.01.003_bib0630","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"},{"key":"10.1016\/j.morpho.2015.01.003_bib0635","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.exphem.2004.07.019","article-title":"Visualization of 5T33 myeloma cells in the C57BL\/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma","volume":"32","author":"Alici","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0640","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-07-0121","article-title":"Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging","volume":"6","author":"Oyajobi","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.morpho.2015.01.003_bib0645","first-page":"3096","article-title":"In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells","volume":"60","author":"Asosingh","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.morpho.2015.01.003_bib0650","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2004.04.012","article-title":"Myeloma cells (5TMM) and their interactions with the marrow microenvironment","volume":"33","author":"Menu","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.morpho.2015.01.003_bib0655","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1179\/his.2001.24.2.81","article-title":"Osteolytic bone lesions in the 5T2 multiple myeloma model: radiographic, scanning electron microscopy and microtomographic studies","volume":"24","author":"Libouban","year":"2001","journal-title":"J Histotechnol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0660","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/bjc.1996.277","article-title":"Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography","volume":"73","author":"Vanderkerken","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.morpho.2015.01.003_bib0665","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.bbrc.2004.02.131","article-title":"Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL\/KaLwRij mouse","volume":"316","author":"Libouban","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.morpho.2015.01.003_bib0670","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence of the secretion of an osteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.morpho.2015.01.003_bib0675","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0680","doi-asserted-by":"crossref","first-page":"e41127","DOI":"10.1371\/journal.pone.0041127","article-title":"Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma","volume":"7","author":"Buckle","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.morpho.2015.01.003_bib0685","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0690","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0695","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2013.090977","article-title":"Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells","volume":"99","author":"Noll","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.morpho.2015.01.003_bib0700","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S8756-3282(03)00196-0","article-title":"Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model","volume":"33","author":"Libouban","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.morpho.2015.01.003_bib0705","first-page":"S35","article-title":"Dietary calcium deficiency increases osteolysis and modifies gene expression profile in an animal model of multiple myeloma","volume":"82","author":"Libouban","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.morpho.2015.01.003_bib0710","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.micron.2013.08.010","article-title":"Plasma cells release membrane microparticles in a mouse model of multiple myeloma","volume":"54\u201355","author":"Benameur","year":"2013","journal-title":"Micron"},{"key":"10.1016\/j.morpho.2015.01.003_bib0715","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neo.2014.07.002","article-title":"SAMSN1 is a tumor suppressor gene in multiple myeloma","volume":"16","author":"Noll","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.morpho.2015.01.003_bib0720","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/icb.1995.50","article-title":"Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model","volume":"73","author":"Manning","year":"1995","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0725","first-page":"457","article-title":"Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype","volume":"38","author":"Croese","year":"1991","journal-title":"Neoplasma"},{"key":"10.1016\/j.morpho.2015.01.003_bib0730","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y","article-title":"Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma","volume":"55","author":"Radl","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.morpho.2015.01.003_bib0735","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0740","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.morpho.2015.01.003_bib0745","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/ijc.22478","article-title":"Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo","volume":"120","author":"Edwards","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.morpho.2015.01.003_bib0750","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1359\/jbmr.1999.14.12.2048","article-title":"Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment","volume":"14","author":"Derenne","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.morpho.2015.01.003_bib0755","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.micron.2014.10.001","article-title":"Unwrapping microcomputed tomographic images for measuring cortical osteolytic lesions in the 5T2 murine model of myeloma treated by bisphosphonate","volume":"68","author":"N\u2019Diaye","year":"2015","journal-title":"Micron"},{"key":"10.1016\/j.morpho.2015.01.003_bib0760","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1111\/bph.12742","article-title":"Novel therapeutic targets in myeloma bone disease","volume":"171","author":"Webb","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0765","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.morpho.2015.01.003_bib0770","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.morpho.2015.01.003_bib0775","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bone.2013.12.025","article-title":"Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors","volume":"61","author":"Zangari","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.morpho.2015.01.003_bib0780","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2967\/jnumed.112.111997","article-title":"213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma","volume":"54","author":"Cherel","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.morpho.2015.01.003_bib0785","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.nucmedbio.2014.02.008","article-title":"Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and melphalan chemotherapy","volume":"41 Suppl.","author":"Gouard","year":"2014","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0790","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bcp.2014.03.013","article-title":"In vivo models of multiple myeloma (MM)","volume":"89","author":"Sanchez","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.morpho.2015.01.003_bib0795","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM197206152862402","article-title":"Ineffectiveness of fluoride therapy in multiple myeloma","volume":"286","author":"Harley","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.morpho.2015.01.003_bib0800","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1056\/NEJM197512252932602","article-title":"Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo","volume":"293","author":"Kyle","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.morpho.2015.01.003_bib0805","first-page":"5","article-title":"Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone","author":"Pennisi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.morpho.2015.01.003_bib0810","doi-asserted-by":"crossref","first-page":"804182","DOI":"10.1155\/2014\/804182","article-title":"Serum parathyroid hormone is a new potential risk factor in multiple myeloma","volume":"2014","author":"Kang","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.morpho.2015.01.003_bib0815","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","article-title":"Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo","volume":"111","author":"Edwards","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.morpho.2015.01.003_bib0820","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"}],"container-title":["Morphologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1286011515000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1286011515000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T01:57:07Z","timestamp":1598925427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1286011515000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":82,"journal-issue":{"issue":"325","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1286011515000223"],"URL":"https:\/\/doi.org\/10.1016\/j.morpho.2015.01.003","relation":{},"ISSN":["1286-0115"],"issn-type":[{"value":"1286-0115","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of animal models in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Morphologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.morpho.2015.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}